Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU approval expiry postponed for two rodenticides

The EU approval expiry dates for the non-crop rodenticides, difenacoum and difethialone, have been postponed until June 30th 2018. The decision was taken because a study on risk mitigation measures for anticoagulant rodenticides had not been completed. The European Commission confirmed the new expiry date after a positive vote by the EU regulatory committee in May (Agrow No 689, p 12). Difenacoum and difethialone approvals were due to expire on March 31st 2015 and October 31st 2014, respectively, and applications for their renewal have been submitted. However, the conclusions of the study are required before any decision can be taken on renewing the authorisations, and all applicants for anticoagulants should be given time to address the study’s findings, the Commission says. It expects to receive applications for renewal of the other anticoagulants, brodifacoum, warfarin and warfarin sodium, by July 2015.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG002148

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel